From Surf Wiki (app.surf) — the open knowledge base

Veliparib

Chemical compound

| elimination_half-life =

Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.

It inhibits both PARP1 and PARP2 and thereby induces synthetic lethality. It is still being evaluated for the treatment of ovarian cancer.

Development

Veliparib is being developed by AbbVie. It was derived from a prior lead compound (A 620223). The FDA awarded orphan drug status in November 2016 for NSCLC.

Clinical trials

As of 2017, 96 clinical trials involving veliparib had been registered with the FDA. It was included in the I-SPY2 breast cancer trial.

Numerous phase I clinical trials are in progress. Over 40 phase II clinical trials have been registered, for indications such as metastatic melanoma, NSCLC, prostate cancer and brain tumors associated with metastatic primary tumors.

Combination trials have evaluated veliparib in combination with doxorubicin, temozolomide, topotecan, carboplatin, paclitaxel, pemetrexed, cyclophosphamide, gemcitabine, and others.

By June 2014 it was in three phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). In 2017, AbbVie reported that veliparib failed to improve outcomes in the triple-negative breast cancer and NSCLC trials.

References

(May 2007). "ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models". Clinical Cancer Research.
(February 2020). "Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach". Investigational New Drugs.
"Veliparib - Abbvie". Springer Nature Switzerland AG.
(March 2010). "Breast cancer study aims to speed drugs, cooperation". Reuters.
link. "106 Studies found for: ABT-888". ClinicalTrialsGov. U.S. National Library of Medicine
{{ClinicalTrialsGov. NCT01009788. A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
{{ClinicalTrialsGov. NCT01576172. Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
(June 2014). "AbbVie takes PARP inhibitor into third phase III trial.". PMGroup.
(20 April 2017). "AbbVie PARP inhibitor veliparib flunks two phase 3 trials". Fierce Biotech.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

experimental-cancer-drugs parp-inhibitors

Want to explore this topic further?

Ask Mako anything about Veliparib — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report